Epinephrine

Evidence Level: L5

Predicted Indications: 3

Epinephrine

Pharmacist Assessment Report

Epinephrine: Obstructive lung disease

One-Sentence Summary

Epinephrine is a non-selective adrenergic agonist, originally used for conditions such as asthma, bronchitis, anaphylaxis, and open-angle glaucoma. The TxGNN model predicts it may be effective for obstructive lung disease, with 15 clinical trials and 20 publications currently supporting this direction. This is largely an extension of established use (asthma, bronchitis, emphysema) rather than a true new indication.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Obstructive lung disease
TxGNN Prediction Score	0.9971
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data
Number of Listed Products	8 (valid: 8)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, epinephrine stimulates both beta and alpha adrenergic receptors. Beta-2 stimulation relaxes bronchial smooth muscle and produces bronchodilation, while alpha-1 stimulation reduces mucosal edema and airway secretions.

Obstructive lung disease covers asthma and chronic obstructive pulmonary disease (COPD). Epinephrine is already associated with asthma, bronchitis, and emphysema, so this prediction is mostly an extension of established use. Evidence in the pediatric bronchiolitis subpopulation is mixed and shows limited sustained benefit.

Clinical Trial Evidence

Fifteen trials were compiled; the 10 most relevant are listed below.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01357642	Phase 3	Completed	373	12-week efficacy and safety of epinephrine HFA inhalation aerosol vs placebo and Primatene Mist in adolescents and adults with asthma
NCT01476904	Phase 3	Completed	208	3-month double-blind safety extension of inhaled epinephrine (E004) in asthma, giving a 6-month safety profile
NCT01460511	Phase 3	Completed	70	4-week placebo-controlled study of E004 in children aged 4-11 with asthma
NCT01737905	Phase 3	Completed	28	Single-dose crossover study of E004 in children aged 4-11 with asthma
NCT01705964	Phase 4	Completed	49	IM epinephrine as an adjunct to inhaled beta-2 agonists in severe pediatric asthma exacerbation
NCT04207840	Phase 4	Completed	28	Systemic exposure of Primatene Mist vs IM epinephrine vs ProAir in healthy adults
NCT01255709	Phase 2	Completed	24	Pharmacokinetics of epinephrine inhalation aerosol (E004) in healthy volunteers
NCT01834820	Phase 4	Completed	120	Epinephrine, dexamethasone and hypertonic saline in bronchiolitis (combination design, so effect is hard to attribute)
NCT00817466	Phase 4	Unknown	500	Optimal inhalation treatment for infants with acute bronchiolitis (results uncertain)
NCT00114478	N/A	Unknown	600	Epinephrine vs albuterol in bronchiolitis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35093318	2022	RCT	The Journal of Pediatrics	Corticosteroids plus nebulized epinephrine vs standard care for duration of positive pressure support in bronchiolitis in intensive care
33893229	2021	Network meta-analysis	Pediatrics	Comparative efficacy of bronchiolitis interventions in acute care
21678340	2011	Systematic review (Cochrane)	Cochrane Database of Systematic Reviews	Epinephrine for bronchiolitis
14974006	2004	Systematic review (Cochrane)	Cochrane Database of Systematic Reviews	Earlier Cochrane review of epinephrine for bronchiolitis
35953216	2022	Review	Emergency Medicine Clinics of North America	Emergency department evaluation and management of asthma and COPD exacerbations
30488718	2019	Review	Expert Review of Respiratory Medicine	Role of racemic epinephrine, corticosteroids, hypertonic saline and high-flow oxygen in pediatric bronchiolitis
21157348	2011	Review	Current Opinion in Pediatrics	No bronchiolitis treatment has conclusively been shown to alter disease course
23393929	2012	Review	Duodecim	Bronchiolitis overview; inhaled racemic epinephrine may be used when required
11940264	2002	Review	Critical Care	Clinical review of severe asthma and status asthmaticus
30856157	2019	Other	The Medical Letter on Drugs and Therapeutics	Return of OTC Primatene Mist

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
5924	Adroglare 1mg Injection	Vial of 1 ml injection	Not available
73948	Enatrate Injection	Vial of 1 ml injection	Not available
73617	Epitrate Injection 1 ml	Vial of 1 ml injection	Not available
3008	Adraclor Injection	Ampoule of 1 ml injection	Not available
233294	Vasocon Injection	Vial of 1 ml injection	Not available

All 8 registrations are valid injectables. No inhaled product is registered in India according to the compiled data.

Review correction (2026-11-06): Originally stated: “All 8 registrations are valid single-ingredient injectables.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.

Safety Considerations

Contraindications (not from label text): hypertension, coronary artery disease, myocardial infarction, atrial fibrillation, heart conduction disease, sudden cardiac arrest, angle-closure glaucoma, diabetes mellitus and diabetic ketoacidosis, hyperthyroidism, liver and kidney disease, epilepsy, benign prostatic hyperplasia, respiratory failure, and myasthenia gravis, among others.
Drug Interactions: 385 interactions were identified. Major-level interactions include amitriptyline and amoxapine. Moderate-level interactions include beta-blockers (acebutolol, atenolol, betaxolol), other beta-agonists (formoterol, salbutamol, arformoterol), stimulants (amphetamine, methylphenidate, atomoxetine), antidiabetic agents (acarbose, alogliptin, albiglutide, acetohexamide), and antipsychotics (amisulpride, aripiprazole, asenapine).

Please also refer to the package insert for label-level warnings.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Several completed Phase 3 trials of inhaled epinephrine in asthma support efficacy and safety, and the use is consistent with established indications. However, the available product in India is injectable only, and the bronchiolitis evidence is mixed.

To proceed, the following is needed:

Package insert warnings, contraindications, and approved indication text for the Indian licenses
Detailed mechanism of action data
Route and formulation assessment (inhaled vs injectable) for the obstructive lung disease use
Cardiovascular risk screening and interaction management plan, especially for patients on tricyclic antidepressants and beta-blockers

Other Predicted Indications (for reference)

Predicted Indication	TxGNN Score	Evidence Level	Decision	Comment
Rienhoff syndrome	0.9957	L5	Hold	No mechanistic rationale, trials, or literature; computational prediction only
Respiratory malformation	0.9956	L3	Hold	Only a Phase 1 trial in transient tachypnea of the newborn (not a structural malformation); retrieved literature is largely off-target

Review Log

Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.

Review date	Item	Action	Source
2026-11-06	Removed: “single-ingredient”	Corrected	Indian Medicine Dataset

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.